Clinical Case Report

Effectiveness of beinaaglutide in a patient with late dumping syndrome after gastrectomy
A case report

Bo Ding, MD, Yun Hu, MD, Lu Yuan, MD, Reng-Na Yan, MA, Jian-Hua Ma, MD

Abstract
Rationale: Dumping syndrome is a frequent and potentially severe complication after gastric surgery. Beinaaglutide, a recombinant human glucagon-like peptide-1 (GLP-1) which shares 100% homology with human GLP-1(7-36), has never been reported in the treatment of dumping syndrome before.

Patient concerns: The patient had undergone distal gastrectomy for gastric signet ring cell carcinoma 16 months ago. He presented with symptoms of paroxysmal palpitation, sweating, and dizziness for 4 months.

Diagnosis: He was diagnosed with late dumping syndrome.

Interventions and outcomes: The patient was treated with dietary changes and acarbose for 4 months before admitted to our hospital. The treatment with dietary changes and acarbose did not prevent postprandial hyperinsulinemia and hypoglycemia according to the 75g oral glucose tolerance test (OGTT) and continuous glucose monitoring (CGM) on admission. Therefore, the patient was treated with beinaaglutide 0.1 mg before breakfast and lunch instead of acarbose. After the treatment of beinaaglutide for 1 month, OGTT showed a reduction in postprandial hyperinsulinemia compared with before starting treatment, and the time in the range of 3.9 to 10 mmol/L became 100% in CGM. No side effect was observed in this patient during beinaaglutide treatment.

Lessons: These findings suggest that beinaaglutide may be effective for treating post-gastrectomy late dumping syndrome.

Abbreviations: ACTH = adrenocorticotropic hormone, ALP = alkaline phosphatase, ALT = alanine aminotransferase, AST = aspartate aminotransferase, BUN = blood urea nitrogen, CGM = continuous glucose monitoring, CP = C-peptide, CV = coefficient of variation, FT3 = free triiodothyronine, FT4 = free thyroxine, GH = growth hormone, GIP = gastric inhibitory polypeptide, GLP-1 = glucagon-like peptide-1, GLP-1RAs = glucagon-like peptide-1 receptor agonists, HbA1c = glycated hemoglobin, HDL-c = high density lipoprotein cholesterol, IGF-1 = insulin-like growth factor-1, LDH = lactate dehydrogenase, LDL-c = low density lipoprotein cholesterol, OGTT = oral glucose tolerance test, RBC = red blood cell, SD = standard deviation, TBR = the time below the range, TC = total cholesterol, TG = triglyceride, TIR = time in range, TSH = thyroid stimulating hormone, WBC = white blood cell.

Keywords: continuous glucose monitoring, dumping syndrome, glucagon-like peptide-1 receptor agonists

1. Introduction

Dumping syndrome is a frequent and potentially severe complication after gastric surgery.\(^1\) Late dumping syndrome is character-ized by a rapid influx of carbohydrates into the upper jejunum, rapidly increased absorption into the intestine, insulin hypersecretion, and clinical hypoglycemia 2 to 3 hours after a meal.

Although glucagon-like peptide-1 receptor agonists (GLP-1RAs) are reported as a treatment of glucose lowering by the inhibition of glucagon secretion and promotion of insulin secretion in patients with type 2 diabetes,\(^2\) and one of the underlying causes of late dumping syndrome is thought to be the postoperatively elevated glucagon-like peptide-1 (GLP-1) levels lead to pancreatic beta cell hypertrophy,\(^3,4\) liraglutide, a GLP-1RA shares 97% homology with human GLP-1, has recently been reported as useful for late dumping syndrome.\(^5-7\) Exenatide, another GLP-1RA, shares less homology with human GLP-1 than liraglutide, was also used in one case of dumping syndrome.\(^7\) Beinaaglutide, a new recombinant human GLP-1, shares 100% homology with human GLP-1(7-36). In this clinical case, we describe the successful use of beinaaglutide in a patient with late dumping syndrome after gastrectomy who failed with acarbose treatment.

2. Case presentation and management

A 53-year-old man, who 16 months previously had undergone distal gastrectomy for gastric signet ring cell carcinoma (stage Ia), presented with symptoms of paroxysmal palpitation, sweating,
and dizziness since February 2020. These symptoms could be remitted by eating. He was diagnosed with dumping syndrome due to a blood glucose level of 1.8 mmol/L 2 hours after breakfast without islet cell tumor in April 2020. Since then, he has been treated with acarbose (25 mg, three times a day), and dietary variation (CV) of glucose were significantly decreased although the time in range of 3.9 to 10 mmol/L (TIR) became 100%, and the coefficient of variation (CV) of glucose were significantly decreased although the 24-hour mean glucose did not change a lot (Fig. 1C–F).

The continuous glucose monitoring (CGM) on admission showed that 23.43% of all glucose values were in the hypoglycemic range of <3.9 mmol/L, and the time below the range (TBR) of <3.0 mmol/L was 5.03% (Fig. 1C and F). The time above the range of >10 mmol/L was 1.74 (%).

After the injection of beinaglutide 0.1 mg before breakfast and lunch instead of acarbose since Sep 1, 2020, the CGM showed that the time in range of 3.9 to 10 mmol/L (TIR) became 100%, and the standard deviation (SD) of 24-hour glucose and the coefficient of variation (CV) of glucose were significantly decreased although the 24-hour mean glucose did not change a lot (Fig. 1C–F).

The symptoms of paroxysmal palpitation, sweating, and dizziness have been in remission since beinaglutide treatment. OGTT and CGM were performed again after 1-month treatment of beinaglutide, and the insulin levels in the OGTT were decreased after beinaglutide treatment (Fig. 1B). The peak of glucose delayed to 60 minutes, while the peak of insulin remained at 60 minutes and decreased to 147.5 mU/L (Fig. 1B). We also tested glucagon levels in OGTT after 1 month, and the results showed that the fasting glucagon was 296.39 pg/mL and the lowest glucagon level was 170.67 at 180 minutes in the OGTT. After beinaglutide treatment for 1 month, the 24-hour mean blood glucose was 5.96 mmol/L and SD of blood glucose was 0.62 mmol/L. His CV was 10.47% and was even lower than that at the beginning of beinaglutide treatment (12.35%). The TIR of 3.9 to 10.0 mmol/L remained 100% (Fig. 1C–F). Moreover, the insulinoenic index was higher after 1-month treatment compared with baseline (Fig. 1G).

Moreover, there was no side effect, such as nausea, dizziness, or loss of appetite in this case. The patient had an unexpectedly improvement in his anxiety and gained 2.5 kg of weight after 1-month beinaglutide treatment (Fig. 1H).

The study was approved by the Institutional Ethical Committee of Nanjing First Hospital, Nanjing Medical University. Informed consent for publication of the case was obtained from the patient included in the case report.

### Table 1

| Laboratory data on admission. | Normal range | Fasting blood test | Normal range |
|------------------------------|--------------|--------------------|--------------|
| WBC (×10^9/L)                | 3.8-9.5      | Blood glucose, mmol/L | 3.9-5.6      |
| RBC (×10^12/L)               | 4.15-5.8     | Insulin, mU/L       | 7.7          |
| Hemoglobin, g/L              | 130-175      | CP, ng/mL           | 2.07         |
| Platelet (×10^9/L)           | 116-350      | ACTH, pg/mL         | 16.5         |
| ALT, U/L                     | 5-50         | Cortisol, μg/dL     | 11.35        |
| AST, U/L                     | 15-40        | GH, ng/mL           | 0.187        |
| ALP, U/L                     | 45-125       | IGF-1, ng/mL        | <2.47        |
| LDH, U/L                     | 120-250      | Calcium, mmol/L     | 2.16         |
| BUN, mmol/L                  | 4.64         | Potassium, mmol/L   | 3.64         |
| Creatinine, μmol/L           | 5.3-123      | Sodium, mmol/L      | 147.9        |
| Potassium, mmol/L            | 3.64         | Calcium, mmol/L     | 2.16         |
| TC, mmol/L                   | 3.12-5.98    | TC, mmol/L          | 4.83         |
| Triglyceride, mmol/L         | 0.86         | ACTH, pg/mL         | 16.8         |
| LDL-c, mmol/L                | 1.37         | Cortisol, μg/dL     | 6.0          |
| HDL-c, mmol/L                | 2.21         | GH, ng/mL           | 8.18         |
| HbA1c, mmol/L                | 5.2          | IGF-1, ng/mL        | 235.5        |
| TSH, mU/L                    | 0.35-4.04    | Glucagon, pg/mL     | 152.7        |
| FT3, pmol/L                  | 4.37         | Blood glucose, mmol/L | 3.9-5.6      |
| FT4, pmol/L                  | 11.34        | Insulin, mU/L       | 28.7         |
| Hemoglobin, g/L              | 135          | CP, ng/mL           | 6.23         |
| Fasting blood test           | Normal range |                   |              |

ACTH = adrenocorticotropic hormone, ALP = alkaline phosphatase, ALT = alanine aminotransferase, AST = aspartate aminotransferase, BUN = blood urea nitrogen, CP = C-peptide, FT3 = free triiodothyronine, FT4 = free thyroxine, GH = growth hormone, HbA1c = glycated hemoglobin, HDL-c = high density lipoprotein cholesterol, IGF-1 = insulin-like growth, LDL-c = low density lipoprotein cholesterol, ABC = red blood cell, TC = total cholesterol, TG = triglyceride, TSH = thyroid stimulating hormone, WBC = white blood cell.
Figure 1. The glucose metabolism before and after beinaglutide treatment in the patient with late dumping syndrome. A. Blood glucose levels and B. insulin levels in OGTTs before and 1-month after beinaglutide treatment. C. Blood glucose profile in CGM at baseline, 1-day and 1-month after beinaglutide treatment. D. Mean blood glucose and standard deviation and E. coefficient of variation (CV) calculated with data from CGM. F. Percentage of time in range (TIR) of 3.9 to 10 mmol/L before and after beinaglutide treatment. G. Insulinogenic index = (insulin 30' − insulin 0')/(glucose 30' − glucose 0'). H. The body weight before and after beinaglutide treatment factor-1.
3. Discussion

In this patient with dumping syndrome who had failed treatment with acarbose and diet modification, beinaglutide therapy showed good efficacy on glycemic variation, and the efficacy could persist for 1 month without any side effects.

Accelerated gastric emptying plays an important role in the pathogenesis of late dumping syndrome after gastric surgery, it gives rise to a larger and earlier increase in plasma glucose, insulin, GLP-1, and GIP concentrations, and thus to reactive hypoglycemia. GLP-1RAs can reduce gastric emptying, which leads to the reduction of hunger and food consumption in patients with type 2 diabetes or obesity. In patients with dumping syndrome, GLP-1RAs were also thought to have a therapeutic effect by inhibiting gastric emptying. In the present case, the peak of blood glucose was delayed, which may also attribute to the inhibition of gastric emptying, and the levels of insulin decreased significantly.

Liraglutide is a long-acting GLP-1RA, and it inhibited insulin secretion both before and after meals in a previously reported case with late dumping syndrome, and the TIR was only 84% after the treatment of 1.2 mg liraglutide per day, which was 100% in the present case. In another case report, Abrahamsson et al. treated 5 patients with postprandial hypoglycemia following gastric bypass surgery with liraglutide, and 2 of the patients experienced side effects including nausea and headache. The amino acid sequence of beinaglutide is the same as that of human GLP-1, with a half-life of about 11 minutes. Beinaglutide can be administered with meals flexibly, which also has an inhibitory effect on gastric emptying, and can reduce insulin secretion within a short period of time after meals. Therefore, the treatment of beinaglutide may be more effective and have less side effects than the long-acting GLP-1RAs.

The benefits of beinaglutide in weight loss and glycemic control have been confirmed in patients with type 2 diabetes. However, in this patient with a low body mass index (BMI) of 17.96 kg/m², beinaglutide did not decrease his weight. On the contrary, he gained 2.5 kg after 1-month beinaglutide treatment because of the remission of anxiety symptoms and fear of hypoglycemia after eating.

The effects of beinaglutide on α and β cell function have not been well established since it was only approved by the China Food and Drug Administration for the treatment of T2DM in December 2016. The present case reported the first use of beinaglutide in a patient with dumping syndrome. We described the effect of beinaglutide on inhibiting hyperinsulinemia, which was opposite to the effect of GLP-1RAs on β-cell function in patients with type 2 diabetes. The patient showed a weak response of cortisol, IGF-1, and glucagon to hypoglycemia at baseline, which may attribute to recurrent hypoglycemia. After 1-month beinaglutide treatment, the glucagon levels were not suppressed. However, the glucagon level in OGTT at baseline was missing, which was a limitation. This case was also lack of data of GLP-1 and GIP levels before and after beinaglutide treatment. Previous studies found that inhibition of GLP-1 and GIP levels by octreotide can also improve dumping syndrome. Therefore, the detection of GLP-1 and GIP may further indicate the mechanism of beinaglutide in the treatment of dumping syndrome. Moreover, the long-term effects of beinaglutide on dumping syndrome need to be observed.

In conclusion, beinaglutide is an effective and safety treatment for late dumping syndrome. Our preliminary results suggest that the efficacy and mechanisms of beinaglutide in the treatment of dumping syndrome should be proved by further studies.

Acknowledgments

The authors thank the members of Endocrinology department of Nanjing First Hospital for their support.

Author contributions

Conceptualization: Jianhua Ma.

Data curation: Reng-Na Yan.

Formal analysis: Yun Hu.

Investigation: Bo Ding, Lu Yuan.

Validation: Jianhua Ma.

Writing – original draft: Yun Hu.

Writing – review & editing: Jianhua Ma.

References

[1] Mine S, Sano T, Tsutsu A, et al. Large-scale investigation into dumping syndrome after gastrectomy for gastric cancer. J Am Coll Surg 2010;211:628–36.

[2] Hare KJ, Vilsboll T, Asmar M, Deacon CF, Knop FK, Holst JJ. The glucagonostatic and insulinotropic effects of glucagon-like peptide-1 contribute equally to its glucose-lowering action. Diabetes 2010;59:1765–70.

[3] Miholic J, Hoffmann M, Holst JJ, et al. Gastric emptying of glucose solution and associated plasma concentrations of GLP-1, GIP, and PYY before and after fundoplication. Surg End Oncol 2007;21:309–14.

[4] Dirksen C, Bossen-Moller KN, Jørgensen NB, et al. Exaggerated release and preserved insulinoctropic action of glucagon-like peptide-1 underlie insulin hypersecretion in glucose-tolerant individuals after Roux-en-Y gastric bypass. Diabetologia 2013;56:2679–87.

[5] Chiappetta S, Stier C. A case report: liraglutide as a novel treatment option in late dumping syndrome. Medicine (Madr) 2017;96:e6348.

[6] Ohrstrom CC, Worm D, Hojager A, et al. Postprandial hypoglycemia after Roux-en-Y gastric bypass and the effects of acarbose, sitagliptin, verapamil, liraglutide and paireotide. Diabetes Obes Metab 2019;21:2142–51.

[7] Abrahamsson N, Engstrom BE, Sundbom M, Karlsson FA. GLP1 analogs as treatment of postprandial hypoglycemia following gastric bypass surgery: a potential new indication? Eur J Endocrinol 2013;169:885–9.

[8] Laferrere B, Teixeira J, McGinty J, et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab 2008;93:2479–85.

[9] van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WH. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond) 2014;38:784–93.

[10] Wauters L, Vanuytsel T. Applications of peptide hormone ligands for the treatment of dumping and short bowel syndrome. Curr Opin Pharmacol 2018;43:118–23.

[11] Zhang YL, Zhou C, Li XF, et al. Beinaglutide showed significant weight-loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real-world setting: a 3-month, multicentre, observational, retrospective, open-label study. Obes Sci Pract 2019;5:366–73.

[12] Wu S, Gao L, Cipriani A, et al. The effects of incretin-based therapies on beta-cell function and insulin resistance in type 2 diabetes: a systematic review and network meta-analysis combining 360 trials. Diabetes Obes Metab 2019;21:973–83.

[13] Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med 2013;369:62–72.

[14] Sato D, Morino K, Ohashi N, et al. Octreotide improves early dumping syndrome potentially through incretins: a case report. Endocr J 2013;60:847–53.